Details for Patent: 10,543,179

Which drugs does patent 10,543,179 protect, and when does it expire?

Patent 10,543,179 protects GILENYA and is included in one NDA.

This patent has forty-one patent family members in seventeen countries.

Summary for Patent: 10,543,179

Patent landscape, scope, and claims:

Title:	Dosage regimen of an S1P receptor modulator
Abstract:	The present invention relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from an inflammatory or autoimmune disorder, for example multiple sclerosis. Specifically, the present invention relates to testing a patient for a history of infection and vaccinating the patient prior to administration of fingolimod or a pharmaceutically acceptable salt thereof at a daily dosage of 0.5 mg.
Inventor(s):	Boulton; Craig (Horsham, GB), Burtin; Pascale (Huningue, FR), David; Olivier (Mulhouse, FR), de Vera; Ana (Basel, CH), Dumortier; Thomas (Basel, CH), Hunt; Irene (Basel, CH), Schmouder; Robert (Berkeley Heights, NJ), Collins; William C. (Basel, CH)
Assignee:
Application Number:	15/986,992
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,543,179
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,543,179

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-001	Sep 21, 2010	AB	RX	Yes	Yes	10,543,179					TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS BY DETERMINING VARICELLA ZOSTER VIRUS (VZV) STATUS AND VACCINATING PRIOR TO COMMENCING TREATMENT

International Family Members for US Patent 10,543,179

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010101513
Australia	2010300918
Australia	2010300919